MedTrace Logo

Liraglutide to Improve corONary Haemodynamics During Exercise streSS

NCT02315001 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-05-20

No results posted yet for this study

Summary

A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1 receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress testing, in those patients with reversible myocardial ischaemia and obstructive coronary artery disease confirmed by a baseline exercise test and coronary angiography respectively.

Conditions

Interventions

DRUG

Liraglutide

GLP-1 receptor agonist administered via subcutaneous injection

OTHER

Placebo

Volume-matched normal saline placebo administered via subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Michael Marber, PhD FRCP · King's College London

  • Simon Redwood, MD FRCP · King's College London

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315001 on ClinicalTrials.gov